The Latest Breaking News from Omicron

India’s first indigenously developed mRNA vaccine against the dominant Omicron variant of the COVID-19 coronavirus will cost ₹2,292, Sanjay Singh, CEO, Gennova Biopharmaceuticals, said at a press conference on June 24.

So the California Court of Appeal has held, concluding that there is enough of a factual dispute (under California's plaintiff-friendly pleading standards) for the case to go forward.

In early 2021, recommendations about COVID vaccines were pretty straightforward – get two doses, as soon as you are eligible. A year later, we knew getting a third dose was important for protection against the new Omicron variant.

India’s first indigenous mRNA vaccine for the Omicron variant, GEMCOVAC-OM, developed by Pune-based Gennova Biopharmaceuticals Ltd, was approved under emergency use guidelines by the Drug Controller General of India late on June 19. This comes a year after the company got approval for GEMCOVAC-19, the country’s first m-RNA vaccine against…

The next round of COVID-19 vaccines will target one of the latest versions of the coronavirus

COVID-19 shots should be reformulated to target an XBB subvariant of the highly infectious omicron strain to provide the best protection during the U.S. fall and winter season, health regulators said.

A panel of advisers to the Food and Drug Administration has recommended revising the current COVID-19 vaccine so that it specifically targets omicron.

The COVID-19 vaccines are on track for a big recipe change this fall

Australia is in its fifth COVID wave, which has been brewing since February. It has grown slowly so many people may have not realised it.

Each Omicron wave so far in Australia has had distinguishing features – the sharp rise and fall of BA.1, the widespread transmission among children and families in BA.2, a shift to more infections in older people with BA.5, then the confusing variant mix in the summer wave of 2022-23.

Scientists debate the benefits of bivalent and monovalent shots